-
MyChart
Log in to our secure, personalized website to manage your care (formerly myMDAnderson).
-
Request an Appointment
Request an Appointment
If you are ready to make an appointment, select a button on the right. If you have questions about MD Anderson’s appointment process, our information page may be the best place to start.
Appointment Information - Donate Today
Study #2016-1130
A PHASE I STUDY OF DS-3201B IN SUBJECTS WITH ACUTE MYELOGENOUS LEUKEMIA (AML) OR ACUTE LYMPHOCYTIC LEUKEMIA (ALL)
Study Status
Open
Treatment Agent
DS-3201
Principal Investigator
Naval Daver
Description
There are 2 parts in this study: Part 1 (dose escalation) and Part 2 (dose expansion). The goal of Part 1 of this clinical research study is to find the highest tolerable dose of DS-3201b that can be given to patients with acute myelogenous leukemia (AML) or acute lymphocytic leukemia (ALL). The goal of Part 2 of this study is to learn if the dose of DS-3201b found in Part 1 can help to control AML or ALL. The safety of DS-3201b will be studied in both parts.
General Information
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: DS-3201
Treatment Location: Both at MDACC & and Other Sites
Sponsor: Daiichi Sankyo, Inc
Study Status
IRB Review and Approval Date: 03/29/2017
Recruitment Status: Open
Projected Accrual: 61
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Malignant neoplasms stated as primary lymphoid haematopoietic
Study phase:
Phase I
Physician name:
Naval Daver
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789